HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- COVID-19 and cancer: How to protect ‘the most vulnerable’ during pandemic Mark Leiser; Jennifer R. Southall; John DeRosier
-
- When there are (almost) no data John Sweetenham, MD, FRCP, FACP
- KTE-X19 induces durable responses in relapsed, refractory mantle cell lymphoma Mark Leiser
- Sitagliptin reduces acute GVHD after peripheral blood stem cell transplantation Mark Leiser
- Ado-trastuzumab emtansine extends DFS in early-stage HER2-positive breast cancer Jennifer R. Southall
- Tailored rivaroxaban regimens safe, effective for children with venous thromboembolism John DeRosier
- Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma John DeRosier
- Novel small-molecule inhibitor ‘quite promising’ in advanced kidney cancer Jennifer R. Southall
- Residual cancer burden predicts long-term outcomes across breast cancer subtypes Mark Leiser
-
- Early-onset gastric cancer, distinct from traditional disease, on the rise in US Jennifer R. Southall
- Bleomycin regimen for germ cell cancer linked to increased cardiovascular risk John DeRosier
- FDA committee votes against approval of Tookad for localized prostate cancer Alexandra (Sasha) Todak
- FDA approves neratinib regimen for HER2-positive metastatic breast cancer
- FDA approves Sarclisa regimen for adults with advanced multiple myeloma
- Jefferson's Kimmel Cancer Center names director of bone marrow transplant, immune cellular therapy
- American Cancer Society names Medal of Honor recipients
- Cedars-Sinai names lung cancer specialist head of medical oncology
-
- Association names lectureship award after lung cancer specialist
- Medical oncologist to receive award for cancer drug development